The QMN Weekly Bulletin

Companies manufacturing and distributing unapproved oxycodone products have 45 days to stop producing the pain meds and 90 days to cease shipping them or risk ramped up FDA enforcement. The agency warning, published in the July 6 Federal Register, covers oral forms of unapproved single-ingredient, immediate-release oxycodone products. Failure to comply could result in seizure, injunction or other judicial or administrative proceedings, the agency said Thursday.
Drug Industry Daily